Brief: Neurotech International Says European Commission Grants NTI164 Orphan Drug Designation
31/03/2025 02:41
March 31 (Reuters) - Neurotech International Ltd NTI.AX: EUROPEAN COMMISSION GRANTS NTI164 ORPHAN DRUG DESIGNATION FOR RETT SYNDROME Source text: ID:nASX7mB2tp Further company coverage: NTI.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurotech International
See all newsBrief: Neurotech International Says Anthony Filippis Resigns As CEO, MD
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt